Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Seeking Alpha

Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...
TechJuice

Vivo’s Next Gaming Flagship Is Coming Soon with Top-Tier Specs

Vivo’s next gaming flagship is coming soon with top-tier specs, advanced cooling, and a high refresh rate display for serious ...
Benzinga.com

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and ...
Seeking Alpha

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...
Nasdaq

Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic

Kennewick, WA, July 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in Precision Radionuclide TherapyTM (PRnT) solutions, today announced the submission of its Investigational Device ...
Nasdaq

Vivos Therapeutics, Inc. to Release First Quarter 2025 Financial Results on May 15, 2025

Vivos Therapeutics, Inc. announced it will release its first quarter 2025 financial results on May 15, 2025, after market close, followed by a conference call at 5:00 p.m. ET to discuss the results ...